Literature DB >> 24389220

Application of adipose-derived stem cells in critical limb ischemia.

Kangkang Zhi1, Zhiwei Gao1, Jun Bai1, Yongfa Wu1, Sili Zhou1, Maoquan Li2, Lefeng Qu1.   

Abstract

Peripheral artery disease is growing in global prevalence. Its most severe form, critical limb ischemia (CLI), is associated with high rates of limb loss, morbidity, and mortality. Neovascularization is the cornerstone of limb preservation in CLI. In the field of regenerative medicine, basic research and preclinical studies have been conducted using mesenchymal stem cells (MSCs) from adult tissues, including bone marrow and adipose tissue, to overcome clinical shortcomings. Adipose-derived stem cells (ASCs) display stable growth and proliferation kinetics and can differentiate into osteogenic, chondrogenic, adipogenic, myogenic or neurogenic lineages. ASCs are readily available from autologous adipose tissue, and have significant potential for tissue repair under conditions of myocardial infarction, heart failure, hind limb ischemia, and inflammation. This review highlights some of the key reports underlining the potential of ASCs, particularly in diseases involving neovascularization.

Entities:  

Mesh:

Year:  2014        PMID: 24389220     DOI: 10.2741/4243

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  9 in total

1.  Peripheral Blood-Derived Mesenchymal Stromal Cells Promote Angiogenesis via Paracrine Stimulation of Vascular Endothelial Growth Factor Secretion in the Equine Model.

Authors:  Leen Bussche; Gerlinde R Van de Walle
Journal:  Stem Cells Transl Med       Date:  2014-10-13       Impact factor: 6.940

2.  Advancing biomaterials of human origin for tissue engineering.

Authors:  Fa-Ming Chen; Xiaohua Liu
Journal:  Prog Polym Sci       Date:  2015-03-28       Impact factor: 29.190

3.  Human Adipose Stromal Cells Increase Survival and Mesenteric Perfusion Following Intestinal Ischemia and Reperfusion Injury.

Authors:  Amanda R Jensen; Dominique L Doster; E Bailey Hunsberger; Morenci M Manning; Samantha M Stokes; Daria Barwinska; Keith L March; Mervin C Yoder; Troy A Markel
Journal:  Shock       Date:  2016-07       Impact factor: 3.454

4.  Oxygen-release microspheres capable of releasing oxygen in response to environmental oxygen level to improve stem cell survival and tissue regeneration in ischemic hindlimbs.

Authors:  Ya Guan; Ning Gao; Hong Niu; Yu Dang; Jianjun Guan
Journal:  J Control Release       Date:  2021-01-27       Impact factor: 9.776

5.  Periostin enhances adipose-derived stem cell adhesion, migration, and therapeutic efficiency in Apo E deficient mice with hind limb ischemia.

Authors:  Jinbao Qin; Fukang Yuan; Zhiyou Peng; Kaichuang Ye; Xinrui Yang; Lijia Huang; Mier Jiang; Xinwu Lu
Journal:  Stem Cell Res Ther       Date:  2015-07-24       Impact factor: 6.832

Review 6.  A Molecular and Clinical Review of Stem Cell Therapy in Critical Limb Ischemia.

Authors:  Punam P Parikh; Zhao-Jun Liu; Omaida C Velazquez
Journal:  Stem Cells Int       Date:  2017-11-20       Impact factor: 5.443

Review 7.  Current Status of Angiogenic Cell Therapy and Related Strategies Applied in Critical Limb Ischemia.

Authors:  Lucía Beltrán-Camacho; Marta Rojas-Torres; Mᵃ Carmen Durán-Ruiz
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

Review 8.  Cell Therapy in Patients with Critical Limb Ischemia.

Authors:  Rita Compagna; Bruno Amato; Salvatore Massa; Maurizio Amato; Raffaele Grande; Lucia Butrico; Stefano de Franciscis; Raffaele Serra
Journal:  Stem Cells Int       Date:  2015-08-02       Impact factor: 5.443

9.  Therapeutic angiogenesis using autologous adipose-derived regenerative cells in patients with critical limb ischaemia in Japan: a clinical pilot study.

Authors:  Takeshi Katagiri; Kazuhisa Kondo; Rei Shibata; Ryo Hayashida; Satoshi Shintani; Shukuro Yamaguchi; Yuuki Shimizu; Kazumasa Unno; Ryosuke Kikuchi; Akio Kodama; Keisuke Takanari; Yuzuru Kamei; Kimihiro Komori; Toyoaki Murohara
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.